Comparative Study Between Generic and Ethical Drugs

Abstract

The pharmaceutical landscape is marked by the coexistence of two essential categories of drugs: generic and branded. This review article aims to comprehensively analyze the key aspects, including efficacy, safety, cost-effectiveness, and regulatory considerations, in the ongoing debate surrounding generic and branded drugs. This study systematically evaluates a vast body of literature and clinical trials, encompassing various therapeutic areas and disease conditions, to elucidate the similarities and differences between generic and branded pharmaceuticals. We explore the bioequivalence and quality control measures that underpin generic drug manufacturing, shedding light on their safety and effectiveness. Furthermore, this review delves into the cost-effectiveness of generic drugs, addressing their potential to reduce healthcare expenditure while maintaining therapeutic efficacy. We also discuss the impact of healthcare policies and regulations on the prescription and utilization of generic drugs across different regions. Through this comparative analysis, we aim to provide healthcare professionals, policymakers, and patients with a balanced perspective on the choice between generic and branded drugs. Our findings highlight the importance of individual patient needs, regulatory compliance, and healthcare infrastructure in shaping drug selection and utilization. Ultimately, this review underscores the significance of continued research and evidence-based decision-making in optimizing the use of generic and branded drugs, thereby enhancing healthcare outcomes and promoting accessible, affordable, and high-quality pharmaceutical care for patients worldwide.